Lessons on tumour response: Imaging during therapy with 177lu-dota-octreotate. A case report on a patient with a large volume of poorly differentiated neuroendocrine carcinoma

Theranostics

Volumn 2, Issue 5, 2012, Pages 459-471

  Garske, Ulrike ^a   Sandström, Mattias ^a   Johansson, Silvia ^a   Granberg, Dan ^a   Lundqvist, Hans ^b   Lubber ink, Mark ^a   Sundin, Anders ^a   Eriksson, Barbro ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

177Lu DOTA octreotate; Do simetry; Neuroendocrine tumour; Prrt; Radionuclide therapy

Indexed keywords

NADROPARIN; PREDNISOLONE; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN RECEPTOR; TETRAXETAN OCTREOTATE LU 177; UNCLASSIFIED DRUG;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SIZE; CARCINOMA; CASE REPORT; DOSIMETRY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FUNCTION; LIVER METASTASIS; LUNG EMBOLISM; MULTIPLE CYCLE TREATMENT; NEUROENDOCRINE CARCINOMA; PROTEIN EXPRESSION; SIDE EFFECT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THROMBOCYTOPENIA; TREATMENT RESPONSE;

EID: 84864544217     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.3594     Document Type: Article

References (33)

1. Imhof A, Brunner P, Marincek N, Briel M, Schindler C, Rasch H, Macke HR, Rochlitz C, Muller-Brand J, and Walter MA. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol. 2011; 29(17): 2416-23.
2. Kwekkeboom DJ, Teunissen JJ, Bakker WH, Kooij PP, de Herder WW, Feelders RA, van Eijck CH, Esser JP, Kam BL, and Krenning EP. Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol. 2005; 23(12): 2754-62.
3. Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, Feelders RA, van Aken MO, and Krenning EP. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008; 26(13): 2124-30.
4. Hoefnagel CA. Metaiodobenzylguanidine and somatostatin in oncology: role in the management of neural crest tumours. Eur J Nucl Med. 1994; 21(6): 561-81.
5. Hoefnagel CA, De Kraker J, Valdes Olmos RA, and Voute PA. 131I-MIBG as a first-line treatment in high-risk neuroblastoma patients. Nucl Med Commun. 1994; 15(9): 712-7.
6. Mukherjee JJ, Kaltsas GA, Islam N, Plowman PN, Foley R, Hikmat J, Britton KE, Jenkins PJ, Chew SL, Monson JP, Besser GM, and Grossman AB. Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with (131)I-meta-iodobenzylguanidine [(131)I-mIBG]. Clin Endocrinol (Oxf). 2001; 55(1): 47-60.
7. Luster M, Clarke SE, Dietlein M, Lassmann M, Lind P, Oyen WJ, Tennvall J, and Bombardieri E. Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2008; 35(10): 1941-59.
8. Emami B, Lyman J, Brown A, Coia L, Goitein M, Munzenrider JE, Shank B, Solin LJ, and Wesson M. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991; 21(1): 109-22.
9. Muratet JP, Daver A, Minier JF, and Larra F. Influence of scanning doses of iodine-131 on subsequent first ablative treatment outcome in patients operated on for differentiated thyroid carcinoma. J Nucl Med. 1998; 39(9): 1546-50.
10. Norden MM, Larsson F, Tedelind S, Carlsson T, Lundh C, Forssell-Aronsson E, and Nilsson M. Down-regulation of the sodium/iodide symporter explains 131I-induced thyroid stunning. Cancer Res. 2007; 67(15): 7512-7.
11. Melis M, Forrer F, Capello A, Bijster M, Bernard BF, Reubi JC, Krenning EP, and De Jong M. Up-regulation of somatostatin receptor density on rat CA20948 tumors escaped from low dose [177Lu-DOTA0,Tyr3]octreotate therapy. Q J Nucl Med Mol Imaging. 2007; 51(4): 324-33.
12. Sandstrom M, Garske U, Granberg D, Sundin A, and Lundqvist H. Individualized dosimetry in patients undergoing therapy with (177)Lu-DOTA-D-Phe (1)-Tyr (3)-octreotate. Eur J Nucl Med Mol Imaging. 2010; 37(2): 212-25.
13. Garske U, Sandström M, Johansson S, Sundin A, Granberg D, Eriksson B, Lundqvist H. Minor changes in effective half-life during fractionated 177Lu-Octreotate therapy. Acta Oncol 2012; 51(1): 86-96.
14. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, and Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009; 45(2): 228-47.
15. Stabuc B, Vrhovec L, Stabuc-Silih M, and Cizej TE. Improved prediction of decreased creatinine clearance by serum cystatin C: use in cancer patients before and during chemotherapy. Clin Chem. 2000; 46(2): 193-7.
16. Kos J, Stabuc B, Cimerman N, and Brunner N. Serum cystatin C, a new marker of glomerular filtration rate, is increased during malignant progression. Clin Chem. 1998; 44(12): 2556-7.
17. Moll S, Nickeleit V, Mueller-Brand J, Brunner FP, Maecke HR, and Mihatsch MJ. A new cause of renal thrombotic microangiopathy: yttrium 90-DOTATOC internal radiotherapy. Am J Kidney Dis. 2001; 37(4): 847-51.
18. Valkema R, Pauwels SA, Kvols LK, Kwekkeboom DJ, Jamar F, de Jong M, Barone R, Walrand S, Kooij PP, Bakker WH, Lasher J, and Krenning EP. Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate. J Nucl Med. 2005; 46 Suppl 1: 83S-91S.
19. Esser JP, Krenning EP, Teunissen JJ, Kooij PP, van Gameren AL, Bakker WH, and Kwekkeboom DJ. Comparison of [(177)Lu-DOTA(0),Tyr(3)]octreotate and [(177)Lu-DOTA(0),Tyr(3)]octreotide: which peptide is preferable for PRRT? Eur J Nucl Med Mol Imaging. 2006; 33(11): 1346-51.
20. Reubi JC, Schar JC, Waser B, Wenger S, Heppeler A, Schmitt JS, and Macke HR. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med. 2000; 27(3): 273-82.
21. Kwekkeboom DJ, Bakker WH, Kooij PP, Konijnenberg MW, Srinivasan A, Erion JL, Schmidt MA, Bugaj JL, de Jong M, and Krenning EP. [177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients. Eur J Nucl Med. 2001; 28(9): 1319-25.
22. Kwekkeboom DJ, Kam BL, van Essen M, Teunissen JJ, van Eijck CH, Valkema R, de Jong M, de Herder WW, and Krenning EP. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr Relat Cancer. 2010; 17(1): R53-73.
23. de Jong M, Breeman WA, Bernard BF, Bakker WH, Visser TJ, Kooij PP, van Gameren A, and Krenning EP. Tumor response after [(90)Y-DOTA(0),Tyr(3)]octreotide radionuclide therapy in a transplantable rat tumor model is dependent on tumor size. J Nucl Med. 2001; 42(12): 1841-6.
24. de Jong M, Breeman WA, Bernard BF, Bakker WH, Schaar M, van Gameren A, Bugaj JE, Erion J, Schmidt M, Srinivasan A, and Krenning EP. [177Lu-DOTA(0),Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy. Int J Cancer. 2001; 92(5): 628-33.
25. Cremonesi M, Ferrari M, Bodei L, Tosi G, and Paganelli G. Dosimetry in Peptide radionuclide receptor therapy: a review. J Nucl Med. 2006; 47(9): 1467-75.
26. Barone R, Borson-Chazot F, Valkema R, Walrand S, Chauvin F, Gogou L, Kvols LK, Krenning EP, Jamar F, and Pauwels S. Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship. J Nucl Med. 2005; 46 Suppl 1: 99S-106S.
27. Pauwels S, Barone R, Walrand S, Borson-Chazot F, Valkema R, Kvols LK, Krenning EP, and Jamar F. Practical dosimetry of peptide receptor radionuclide therapy with (90)Y-labeled somatostatin analogs. J Nucl Med. 2005; 46 Suppl 1: 92S-8S.
28. Kunikowska J, Krolicki L, Hubalewska-Dydejczyk A, Mikolajczak R, Sowa-Staszczak A, and Pawlak D. Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option? Eur J Nucl Med Mol Imaging. 2011; 38(10): 1788-97.
29. Brans B, Mottaghy FM, and Kessels A. 90Y/177Lu-DOTATATE therapy: survival of the fittest? Eur J Nucl Med Mol Imaging. 2011; 38(10): 1785-7.
30. Oberg K, Astrup L, Eriksson B, Falkmer SE, Falkmer UG, Gustafsen J, Haglund C, Knigge U, Vatn MH, and Valimaki M. Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms). Part I-general overview. Acta Oncol. 2004; 43(7): 617-25.
31. Oberg K, Astrup L, Eriksson B, Falkmer SE, Falkmer UG, Gustafsen J, Haglund C, Knigge U, Vatn MH, and Valimaki M. Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms). Part II-specific NE tumour types. Acta Oncol. 2004; 43(7): 626-36.
32. Mitry E, Baudin E, Ducreux M, Sabourin JC, Rufie P, Aparicio T, Lasser P, Elias D, Duvillard P, Schlumberger M, and Rougier P. Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer. 1999; 81(8): 1351-5.
33. Ezziddin S, Opitz M, Attassi M, Biermann K, Sabet A, Guhlke S, Brockmann H, Willinek W, Wardelmann E, Biersack HJ, and Ahmadzadehfar H. Impact of the Ki-67 proliferation index on response to peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging. 2011; 38(3): 459-66